Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Franko J, et al. Among authors: de gramont a. Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12. Lancet Oncol. 2016. PMID: 27743922 Free article. Clinical Trial.
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. Tournigand C, et al. Among authors: de gramont a. J Clin Oncol. 2004 Jan 15;22(2):229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2. J Clin Oncol. 2004. PMID: 14657227 Corrected and republished. Clinical Trial.
First-line therapy for advanced colorectal cancer.
de Gramont A, Tournigand C, Louvet C, Maindrault-Goebel F, André T. de Gramont A, et al. Curr Oncol Rep. 2005 May;7(3):167-72. doi: 10.1007/s11912-005-0069-y. Curr Oncol Rep. 2005. PMID: 15847706 Review.
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Coudray AM, Louvet C, Kornprobst M, Raymond E, André T, Tournigand C, Faivre S, De Gramont A, Larsen AK, Gespach C. Coudray AM, et al. Among authors: de gramont a. Int J Oncol. 2005 Aug;27(2):553-61. Int J Oncol. 2005. PMID: 16010439
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. Among authors: de gramont a. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. Tournigand C, et al. Among authors: de gramont a. J Clin Oncol. 2006 Jan 20;24(3):394-400. doi: 10.1200/JCO.2005.03.0106. J Clin Oncol. 2006. PMID: 16421419 Clinical Trial.
398 results